규제 업데이트

A debate in Seoul proposes broadening health‑insurance benefits for continuous glucose monitors to include type 2 diabetes and shifting reimbursement to a device‑support model, which could benefit pharmacies.

Rimkato (Anvalcapatgen Autologous Cell), Korea's first CAR‑T drug, cleared the health‑insurance reimbursement hurdle, signaling a shift toward domestic cell‑gene therapies.

A draft amendment to the Pharmacy Act aims to prohibit 'warehouse‑type' pharmacies, citing concerns over external capital influence and loss of pharmacy independence.

The Korean Pharmaceutical Association held its 295th day relay protest, urging reforms to the Han Yaksa licensing system despite heavy rain.

Daewoong Bio is redesigning packaging for its entire prescription line to improve visual identification and reduce compounding errors, aligning with the MFDS’s July push for safer drug labeling.

Myeongin Pharma seeks Korean approval for P2B001, the world’s first extended‑release Parkinson’s combination drug, as it shifts toward global R&D.

외부 자본이 개입한 '창고형 약국'을 차단하기 위한 법안이 곧 발의돼 약국 독립성과 공공성 확보가 논의됩니다.

MSD Korea received MFDS approval for two additional Keytruda combination therapy indications, bringing its Korean portfolio to 5 bladder and 2 ovarian cancer indications, covering 18 cancers and 37 indications overall.

The Ministry of Health and Welfare is forming a new Health Personnel Task Adjustment Committee to discuss the work scope of pharmacists and herbal pharmacists, with member nominations due by the 24th.

South Korea faces a surge in drug addiction among young adults and urges a shift from punitive measures to disease‑focused, community‑level prevention involving local pharmacies.

Cresoti confirmed unauthorized access to its EasyScanner and PharmDoc services and reported the incident to Korean privacy and cybersecurity authorities.

A policy forum discussed expanding CGM insurance coverage to insulin‑treated type 2 diabetes patients and shifting reimbursement to a direct benefit system.